Expertise. Innovation. Results.

NeoProteomics secures exclusive option agreement with
Case Western Reserve University; receives grant from Great Lakes Innovation Development Enterprise (GLIDE) to develop licensed biomarkers

March 28, 2011 - NeoProteomics Inc. has secured an exclusive option agreement with Case Western Reserve University. The deal has potential to enhance various forms of treatment of cancer, diabetes, and inflammatory diseases.

Mark R. Chance, PhD, said the exclusive option, established through Case Western Reserve's Technology Transfer Office, will greatly help with tools and biomarkers that will permit the company to expand its portfolio in the growing field of personalized medicine.

In addition, funding received from the Great Lakes Innovation Development Enterprise (GLIDE) has enabled the development of biomarkers licensed from the university. Currently, NeoProteomics is distributing software already licensed from Case Western Reserve. The software, ProtMapMSTM, speeds structural biology research by automating mass spectrometry workflows. It has been licensed to major pharmaceutical companies and some of the country’s most prestigious research universities. 

Read more about the exclusive option agreement: News Medical, Mass Device, eBioNews, and GenomeWeb.

Grant brings NeoProteomics one step closer to the bedside
September 11, 2009 - Mark Chance, a physiology and biophysics professor at Case Western Reserve University School of Medicine, accepted a $25,000 grant from the Innovation Fund of the Lorain County Community College Foundation. Chance plans to use the money to help his company, NeoProteomics, commercialize his discovery of a protein marker that can warn diabetics of future kidney disease.

The grant helps NeoProteomics bridge the so-called Valley of Death: the time between research and development, and a move into the marketplace when companies often find it difficult to get funding... Read More.